scholarly journals Concurrent Renal Chronic Kidney Disease-Metabolic Bone Disorder (Renal Hyperparathyroidism) and Noninvasive Benign Thymoma

2014 ◽  
pp. 1-6
Author(s):  
Diaconescu MR ◽  
Glod M ◽  
Grigorovici M ◽  
Diaconescu S
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Hyperparathyroidism ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

scholarly journals From “Kidneys Govern Bones” to Chronic Kidney Disease, Diabetes Mellitus, and Metabolic Bone Disorder: A Crosstalk between Traditional Chinese Medicine and Modern Science

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Xiao-Qin Wang ◽  
Xin-Rong Zou ◽  
Yuan Clare Zhang
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Chinese Medicine ◽  
Calcium Phosphate ◽  
Traditional Chinese Medicine ◽  
Molecular Mechanisms ◽  
Chinese Herbal ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

Although traditional Chinese medicine (TCM) and Western medicine have evolved on distinct philosophical foundations and reasoning methods, an increasing body of scientific data has begun to reveal commonalities. Emerging scientific evidence has confirmed the validity and identified the molecular mechanisms of many ancient TCM theories. One example is the concept of “Kidneys Govern Bones.” Here we discuss the molecular mechanisms supporting this theory and its potential significance in treating complications of chronic kidney disease (CKD) and diabetes mellitus. Two signaling pathways essential for calcium-phosphate metabolism can mediate the effect of kidneys in bone homeostasis, one requiring renal production of bioactive vitamin D and the other involving an endocrine axis based on kidney-expressed Klotho and bone-secreted fibroblast growth factor 23. Disruption of either pathway can lead to calcium-phosphate imbalance and vascular calcification, accelerating metabolic bone disorder. Chinese herbal medicine is an adjunct therapy widely used for treating CKD and diabetes. Our results demonstrate the therapeutic effects and underlying mechanisms of a Chinese herbal formulation, Shen-An extracts, in diabetic nephropathy and renal osteodystrophy. We believe that the smart combination of Eastern and Western concepts holds great promise for inspiring new ideas and therapies for preventing and treating complications of CKD and diabetes.

Development of a quantitative systems pharmacology model of chronic kidney disease - metabolic bone disorder

2020 ◽  
Author(s):  
Adam E Gaweda ◽  
Devin E McBride ◽  
Eleanor D. Lederer ◽  
Michael E. Brier
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Diseases ◽  
Mineral Metabolism ◽  
Individual Variability ◽  
Systems Pharmacology ◽  
Quantitative Systems Pharmacology ◽  
Therapeutic Goals ◽  
Metabolic Bone Disorder ◽  
Bone Disorder

Chronic kidney disease mineral bone disorder (CKD-MBD) is a virtually universal complication of kidney diseases, starting early in the course of disease and resulting in devastating clinical consequences ranging from bone fragility to accelerated atherosclerosis and early cardiovascular death. Guidelines for therapeutic goals for CKD-MBD have been published, and achievement of these guidelines is associated with improved survival. However, the incomplete understanding of CKD-MBD and the individual variability in the manifestations of CKD-MBD has made it difficult to achieve these guidelines. We hypothesized that the progression of MBD through all stages of CKD, including End Stage Kidney Disease could be represented by a Quantitative Systems Pharmacology/Systems Biology (QSP) model. To address this hypothesis, we constructed a QSP model of CKD-MBD, building on an open-source model of calcium and phosphorus metabolism. Specifically, we estimated and validated the model using data from 5496 CKD patients enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study. Our model accurately predicted changes in markers of mineral metabolism related to progressing CKD. We demonstrated that the incorporation of FGF23 and the soft tissue compartment is essential for accurate modeling of the changes in calcium, phosphorus, iPTH and calcitriol in CKD-MBD.

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging

2021 ◽  
Author(s):  
Sharjeel Usmani ◽  
Najeeb Ahmed ◽  
Gopinath Gnanasegaran ◽  
Fahad Marafi ◽  
Tim van den Wyngaert
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Functional Imaging ◽  
Mineral And Bone Disorder ◽  
Bone Disorder
Sign in / Sign up

Export Citation Format

Share Document